We have developed a range of recombinant antibodies that allow targeting of activated platelets, the activated coagulation system, and activated monocytes. Thereby we can specifically image thrombotic and inflammatory processes. We have tailored these antibodies to be used in advanced imaging technologies such as MRI, PET, ultrasound and fluorescence imaging (FLECT, IVIS). We are investigating diseases including atherosclerosis (particularly plaque instability), myocardial infarction and inflammatory diseases such as rheumatoid arthritis and multiple sclerosis.
The biotechnological development of these contrast reagents and particles are an important and highly translational focus in our group.